ClearSight’s proprietary, patent-pending formulation features a powerful antimicrobial biopolymer that effectively targets and eliminates bacterial, fungal, and viral infections associated with pink eye. Unlike antibiotics, this biopolymer acts on the bacterial cell wall, preventing the development of bacterial resistance. Furthermore, ClearSight’s biopolymer can remove biofilm, which is a challenging complication often seen in Dry Eye Disease and infections related to contact lens use.

1. Completed the development of our formulation and the submission of IP regarding the use of Biopolymer for ophthalmic indications.
2. Completed key in-vitro studies for anti-bacterial, anti-fungal, anti-viral, and anti-biofilm activity.
3. Completed two Early-Stage healthcare accelerators: Health Wildcatters (Dallas, TX) in 2024 and MassChallenge (Boston, MA) in 2025.
4. Established partnerships with our key API supplier and a US-based, contract development and manufacturing organization (CDMO).
5. Established partnership with a commercial distribution partner, Dry Eye Rescue, that will allow us to launch both a branded portfolio to be sold B2B->2C via 4K Ophthalmology and Optometry practices.
6. In negotiation with a private label partnership with a Retina Specialist-owned, OTC selling company called Covalent Medical.
7. Submitted 4 separate non-dilutive grants between Jun and Sep (3 DoD grants and 1 NIH SBIR)